A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients with Metastatic Breast Cancer (SPORE).

Trial Profile

A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients with Metastatic Breast Cancer (SPORE).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Cisplatin (Primary) ; Everolimus (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPORE
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 18 Jul 2016 Planned End Date changed from 1 Jan 2014 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top